World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
31548
World Ranking
14473
National Ranking
7319

David I. Quinn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David I. Quinn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 592 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David I. Quinn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David I. Quinn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David I. Quinn is affiliated with the University of Southern California in the United States. Their research primarily spans the field of Medicine, with a focus on subfields such as Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist's work covers several main topics, including:

  • Prostate Cancer Treatment and Research
  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Renal cell carcinoma treatment
  • Radiopharmaceutical Chemistry and Applications
  • Urinary and Genital Oncology Studies
  • Renal and related cancers

Frequent co-authors who have collaborated extensively with David I. Quinn include:

  • Primo N. Lara
  • Daniel P. Petrylak
  • Ian M. Thompson
  • Amir Goldkorn
  • Maha Hussain

The most common publication venues for their work are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • European Urology
  • The Journal of Urology

Recent significant papers authored or co-authored by David I. Quinn include:

  • "Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma," 2021, New England Journal of Medicine
  • "EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma," 2020, Journal of Clinical Oncology
  • "Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial," 2022, The Lancet Oncology
  • "Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial," 2021, The Lancet Oncology
  • "Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry," 2020, Prostate Cancer and Prostatic Diseases

Best Publications

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

  • Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

    John B. Welsh;Lisa M. Sapinoso;Suzanne G. Kern;David A. Brown

  • A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement

    George S. Stergiou;Bruce Alpert;Stephan Mieke;Roland Asmar

  • Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression

    Chia-Wei Cheng;Gregor B. Adams;Laura Perin;Min Wei

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Toni K. Choueiri;Piotr Tomczak;Se Hoon Park;Balaji Venugopal

  • Fasting and cancer treatment in humans: A case series report

    Fernando M. Safdie;Tanya Dorff;David Quinn;Luigi Fontana

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • A PREOPERATIVE NOMOGRAM IDENTIFYING DECREASED RISK OF POSITIVE PELVIC LYMPH NODES IN PATIENTS WITH PROSTATE CANCER

    Ilias Cagiannos;Pierre Karakiewicz;James A. Eastham;Makato Ohori

  • Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer

    Lisa G. Horvath;Susan M. Henshall;C-Soon Lee;Darren R. Head

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    Y Fradet;J Bellmunt;D J Vaughn;J L Lee

  • Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

    Amir Goldkorn;Benjamin Ely;David I. Quinn;Catherine M. Tangen

  • Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    Martin Fassnacht;Alfredo Berruti;Eric Baudin;Michael J Demeure

  • Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.

    Ronaldo J. Bova;David I. Quinn;Jane S. Nankervis;Ian E. Cole

  • Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer

    Kathleen Ell;Bin Xie;Brenda Quon;David I. Quinn

  • Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.

    Susan M. Henshall;Daniel E. H. Afar;Jordan Hiller;Lisa G. Horvath

  • Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer

    Susan M. Henshall;David I. Quinn;C. Soon Lee;Darren R. Head

Frequent Co-Authors

Susan Groshen
Susan Groshen University of Southern California
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Primo N. Lara
Primo N. Lara University of California, Davis
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Celestia S. Higano
Celestia S. Higano University of Washington
Maha Hussain
Maha Hussain Northwestern University
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Inderbir S. Gill
Inderbir S. Gill University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens pathways beyond traditional medical schools. Many students consider alternative healthcare careers that offer flexibility and strong job prospects. For example, becoming a nurse can be a rewarding and in-demand option. Some universities now offer online direct entry MSN programs for non-nurses, allowing those without a nursing background to fast-track into advanced nursing roles.

Admission barriers vary widely between programs. Prospective nurses can look for the easiest BSN program to get into or explore nursing schools that don’t require TEAS test exams, making the application process less stressful.

For those interested in the administrative side of healthcare, the field of medical coding and billing offers online options with financial assistance. The medical billing and coding schools online can prepare you for a healthcare career focused on records management and patient data.

Exploring these related online degrees and alternate career routes ensures you have flexible options as you plan your future in healthcare.

Best Scientists Citing David I. Quinn

Trending Scientists